​​Investigator-Initiated Trials: First Participant Enrolled in The Single-Site, Open-Label Phase 2 Study of MDMA-Assisted Therapy for U.S. Military Veterans with Combat-Related, Refractory PTSD

After 31 years since MAPS first tried to start research into MDMA-assisted therapy for PTSD inside the Veterans Affairs (VA) system, the first study participant has been enrolled in an investigator-initiated trial led by Dr. Shannon Remick at the Loma Linda Department of Veterans Affairs (VA) in Loma Linda, California. The participant is currently undergoing the course of treatment. This study is a single-site, open-label Phase 2 study designed to test the feasibility of administering MDMA in conjunction with therapy for combat-related treatment-resistant PTSD in U.S. military veterans currently enrolled in services at the VA in Loma Linda, California. This study is an investigator-initiated trial and is currently active and recruiting. For more information, visit the official study page on clinicaltrials.gov.